The packet defines myasthenia gravis as an autoimmune disorder of the neuromuscular junction. No genes are listed (known_genes is empty), and the packet's inheritance field carries the single value MULTIFACTORIAL. The packet supplies no molecular mechanism, so the specific immune targets, triggers, and the contribution of genetic or environmental factors are not certified in this packet. Because no genes are listed, the packet does not support a Mendelian inheritance description for this condition.

The packet supplies no diagnostic criteria, test list, or newborn-screening information for myasthenia gravis. Its description of the condition as an autoimmune disorder of the neuromuscular junction with fatigable muscle weakness is the only diagnosis-relevant content. Specific diagnostic approaches are not certified in this packet.

The packet lists eight FDA records for myasthenia gravis with market status ACTIVE and therefore identifies them as current FDA-approved options: nipocalimab (IMAAVY, BLA, approved 2025-04-29), zilucoplan (ZILBRYSQ, NDA, 2023-10-17), rozanolixizumab (RYSTIGGO, BLA, 2023-06-26), efgartigimod alfa and hyaluronidase (VYVGART HYTRULO, BLA, 2023-06-20), efgartigimod alfa (VYVGART, BLA, 2021-12-17), inebilizumab (UPLIZNA, BLA, 2020-06-11), ravulizumab (ULTOMIRIS, BLA, 2018-12-21), and pyridostigmine bromide (NDA, 1965-01-25). Orphan-drug records in the packet list IMAAVY, VYVGART, VYVGART HYTRULO, UPLIZNA, ULTOMIRIS, RYSTIGGO, and ZILBRYSQ as APPROVED for treatment of myasthenia gravis; the packet does not state an indication for pyridostigmine bromide. The packet also lists many orphan-drug designations (status DESIGNATED, which is not approval), including cladribine, iptacopan, cemdisiran, pozelimab with cemdisiran, mezagitamab, telitacicept, rituximab, methotrexate, prednisone, neostigmine methylsulfate, and CAR T-cell products from Kyverna Therapeutics, Cartesian Therapeutics, and Cabaletta Bio. Orphan designations for amifampridine phosphate, mycophenolate mofetil, satralizumab-mwge, monarsen, and tolerogen carry the status WITHDRAWN. One National Organization for Rare Disorders medical assistance program is listed with enrollment status ACCEPTING. The packet contains no GeneReviews management section, so other management approaches are not certified in this packet.

The packet does not contain natural-history, outcome, or survival information for myasthenia gravis. Prognosis is not certified in this packet.

ClinicalTrials.gov data in the packet count 148 active trials for myasthenia gravis, and the packet details ten of them. Examples include a Phase 3 study of ravulizumab in Chinese adults with generalized myasthenia gravis (NCT07596784, recruiting, Alexion Pharmaceuticals), a Phase 3 study of a new oral cladribine formulation compared with placebo (NCT06463587, recruiting, Merck Healthcare KGaA), a Phase 3 extension of rozanolixizumab in pediatric participants (NCT06540144, active not recruiting, UCB Biopharma), a Phase 2 study of SHR-2173 injection (NCT07622342, recruiting, Guangdong Hengrui Pharmaceutical), and a Phase 2 study of inebilizumab pharmacokinetics, pharmacodynamics, and safety (NCT06987539, recruiting, Amgen). Cell-therapy studies include a Phase 1 study of CABA-201 (NCT06359041, recruiting, Cabaletta Bio), a Phase 1 study of KITE-363 in autoimmune neurologic diseases (NCT07304154, recruiting, Kite), and a Phase 1 study of BAFF-R CAR T cells for refractory neuroimmune diseases (NCT07022197, recruiting, Tianjin Medical University General Hospital). Two argenx platform or Phase 2 studies (NCT07294170 and NCT07673627) are also listed as recruiting. The packet's intervention summary notes that gene therapy trials are present among the registered studies, with Alexion Pharmaceuticals, Amgen, and AstraZeneca among the top sponsors. Trial titles do not establish the interventions tested. The packet's publication digest classifies 454 publications, most commonly reviews and meta-analyses (109 reviews and 46 case reports).